Abstract：
This study aims to systematically review the efficacy and safety of Shufeng Jiedu Capsules in the treatment of influenza. The randomized controlled trial(RCT) of Shufeng Jiedu Capsules alone or in combination with conventional western medicine for treating influenza were retrieved from PubMed, EMbase, Cochrane Library, Web of Science, SinoMed, CNKI, VIP, Wanfang, and ClinicalTrails.gov. The data analysis was performed in RevMan 5.4.1. The Cochrane risk of bias assessment tool was used to evaluate the quality of the involved RCT, and GRADEpro GDT to assess the quality of the evidence. A total of 11 RCTs involving 1 836 patients were included in this study. Compared with conventional western medicine, Shufeng Jiedu Capsules/Shufeng Jiedu Capsules + conventional western medicine improved the response rate(RR=1.09, 95%CI[1.03, 1.15], P=0.002), shortened the time to relief of cough, and increased the 3-day sore throat relief rate, whereas there was no significant difference in the time to fever abatement, the time to relief of sore throat, 3-day cough relief rate, or 3-day runny nose relief rate. Subgroup-analysis showed that Shufeng Jiedu Capsules + conventional western medicine improved the response rate(RR=1.11, 95%CI[1.08, 1.15], P<0.000 01), shortened the time to relief of cough, and increased the 3-day relief rate of symptoms(cough, sore throat, and runny nose) compared with conventional western medicine alone, while there was no significant difference in the time to fever abatement or the time to relief of sore throat. Shufeng Jiedu Capsules alone could not improve the response rate(RR=0.97, 95%CI[0.93, 1.02], P=0.19). In addition, Shufeng Jiedu Capsules/Shufeng Jiedu Capsules + conventional western medicine vs conventional western medicine were no significant difference in adverse reactions(RR=0.98, 95%CI[0.57, 1.69], P=0.95). The available evidence suggests that Shufeng Jiedu Capsules is effective and safe in the treatment of influenza, and the combination of Shufeng Jiedu Capsules with conventional western medicine can accelerate the relief of symptoms. However, since the number and quality of the included studies were low, the above findings remained to be further verified by multicenter RCT with large sample sizes.
摘要：
本研究旨在系统评价疏风解毒胶囊治疗流感的有效性和安全性。从PubMed检索疏风解毒胶囊单用或联合常规西药治疗流感的随机对照试验(RCT),EMBase,科克伦图书馆,WebofScience,SinoMed,CNKI,VIP,万方,和ClinicalTrails.gov.数据分析在RevMan5.4.1中进行。Cochrane偏倚风险评估工具用于评估涉及的RCT的质量，和GDT来评估证据的质量。本研究共纳入11项RCTs，涉及1836例患者。与常规西药相比,疏风解毒胶囊/疏风解毒胶囊+常规西药改善缓解率(RR=1.09,95CI[1.03,1.15],P=0.002),缩短了咳嗽缓解的时间，并提高了3天喉咙痛缓解率，而退烧时间没有显着差异，缓解喉咙痛的时间，3天咳嗽缓解率,或3天流鼻涕缓解率。亚组分析显示疏风解毒胶囊+常规西药提高了缓解率(RR=1.11,95CI[1.08,1.15],P<0.00001)，缩短了咳嗽缓解的时间，并增加症状的3天缓解率（咳嗽，喉咙痛,和流鼻涕)与常规西药相比，而退烧时间或咽喉痛缓解时间没有显着差异。单用疏风解毒胶囊不能提高有效率(RR=0.97,95CI[0.93,1.02],P=0.19）。此外,疏风解毒胶囊/疏风解毒胶囊+常规西药与常规西药不良反应比较差异无统计学意义(RR=0.98,95CI[0.57,1.69],P=0.95）。现有证据表明疏风解毒胶囊治疗流感是安全有效的,疏风解毒胶囊与常规西药合用可加速症状缓解。然而,由于纳入研究的数量和质量较低，上述发现还有待大样本量的多中心RCT进一步验证.
